Use of molidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, in chronic kidney disease-associated anemia in cats
Journal of Veterinary Internal Medicine · 2024
DOI: 10.1111/jvim.16807 ↗At a glance
Multizentrische Studie in Journal of Veterinary Internal Medicine, 2024. Written by Samuel Charles and 4 co-authors. Institution: Research and Breakthrough Innovation, Elanco Animal Health Inc., Greenfield, Indiana, USA. Major MEDLINE topics: Anemia, Cat Diseases, Prolyl-Hydroxylase Inhibitors, Pyrazoles. Cited 17 times so far (Crossref); 14 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Elanco Animal Health Inc..
Abstract (original language)
Background
Erythropoietic effects of molidustat, a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, were previously demonstrated in healthy cats.
Objective
To evaluate the safety and erythropoietic effects of daily PO administration of molidustat in anemic cats with chronic kidney disease (CKD). Animals Twenty-one client-owned CKD cats (4-17 years old) with anemia.
Methods
Multicenter field study; randomized, masked, and placebo-controlled. Cats were treated PO once daily for 28 days with suspensions of control product (CP; n = 6) or 5 mg/kg of molidustat (n = 15). Hematocrit (HCT) was evaluated at weekly intervals. Individual cat treatment success was defined as a ≥4% point increase in HCT compared to baseline.
Results
Control group mean HCT remained low throughout the study (20.1%-23.4%). Mean HCT of molidustat-treated cats increased weekly, and a significant increase compared to baseline (23.6%) was first observed on Day 21 (27.3%; P < .001; 95% confidence interval [CI], 1.69-5.67). Compared to CP group, mean HCT was significantly higher on Day 21 (27.3% vs 20.1%; P < .001; 95% CI, 2.91-10.75) but not significantly higher on Day 28 (27.8% vs 23.4%; P = .06; 95% CI, −0.23 to 9.88). The number of individual treatment successes on Day 28 was higher among remaining molidustat-treated cats (7/14) compared to remaining control cats (1/5), but there was no significant difference between groups. Conclusions and Clinical Importance Daily PO molidustat administration may stimulate a clinically relevant erythropoietic response in anemic cats with CKD. This HIF-PH inhibitor may be an alternative for managing anemia in cats compared to recombinant EPO treatment.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Research and Breakthrough Innovation, Elanco Animal Health Inc., Greenfield, Indiana, USA.
- Project and Portfolio Management, Elanco Animal Health Inc., Monheim, Germany.
- Olathe, Kansas, USA.
- Small Animal Internal Medicine, The Ohio State University, Columbus, Ohio, USA.
- IntegRxal Consulting Strategies, Inc., Saskatoon, Saskatchewan, Canada.
ORCID profiles: Catherine Langston, Chantal Lainesse
Funding
- Elanco Animal Health Inc.
Cite
APA
Charles, S., Süssenberger, R., Settje, T., Langston, C., & Lainesse, C. (2024). Use of molidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, in chronic kidney disease-associated anemia in cats. Journal of Veterinary Internal Medicine. https://doi.org/10.1111/jvim.16807
Vancouver
Charles S, Süssenberger R, Settje T, Langston C, Lainesse C. Use of molidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, in chronic kidney disease-associated anemia in cats. Journal of Veterinary Internal Medicine. 2024. doi:10.1111/jvim.16807
BibTeX
@article{Charles2024,
author = {Charles, Samuel and Süssenberger, Ricarda and Settje, Terry and Langston, Catherine and Lainesse, Chantal},
title = {Use of molidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, in chronic kidney disease-associated anemia in cats},
journal = {Journal of Veterinary Internal Medicine},
year = {2024},
doi = {10.1111/jvim.16807}
}
EUVIMED